8-K: FocalTherics Reports Strong Q2 Preliminary Results, Eyes New Markets

FocalTherics announced preliminary Q2 2026 financial results showing significant revenue growth and progress in expanding its Focal One platform into BPH and endometriosis indications.

Summary

• FocalTherics (FOCL) released preliminary unaudited financial results for its HIFU segment for the second quarter of 2026, reporting continuing operations.
• The company is classifying its Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments as discontinued operations.
• Preliminary Q2 2026 HIFU revenue is estimated between $12.7 million and $13.2 million, representing a 34% to 39% year-over-year increase.
• Gross margin for the HIFU segment is projected to be between 54% and 56%, an increase of 3% to 5% from the prior year's quarter.
• As of June 30, 2026, the company reported cash, cash equivalents, and short-term investments of $21.5 million.
• FocalTherics is advancing the evaluation of its Focal One Robotic HIFU platform for Benign Prostatic Hyperplasia (BPH) and deep infiltrating endometriosis.
• The company received FDA Breakthrough Device Designation for endometriosis in 2024 and has initiated a limited commercial launch in Europe.
• Full second quarter 2026 financial results are scheduled to be reported on August 13th.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with strong revenue growth and expansion into new, large market indications, though it is important to note the preliminary nature of the financial results.

Positives

• Strong preliminary revenue growth for the HIFU segment, with an estimated 34% to 39% increase year-over-year for Q2 2026.
• Improvement in gross margin for the HIFU segment, increasing by 3% to 5% compared to Q2 2025.
• Significant growth in Focal One system sales, up 44% year-over-year, reaching 13 units in Q2 2026.
• Expansion of the global HIFU installed base to 184 Focal One systems, a 38% increase from Q2 2025.
• Robust growth in Focal One U.S. procedure volume, up 47% year-over-year.
• Advancement in new indications: BPH feasibility studies are underway with IRB approval in the U.S., and endometriosis development is progressing with a limited commercial launch in Europe.
• FDA Breakthrough Device Designation received for endometriosis in 2024.
• Positive reimbursement trends, with four consecutive annual increases for HIFU for Prostate Cancer and a proposed 11.6% increase for 2027 OPPS.

Negatives

• The financial results reported are preliminary, unaudited, and subject to change.
• The company is classifying its ESWL and Distribution segments as discontinued operations, indicating a strategic shift away from these areas.
• Operating loss for the HIFU segment is projected to be between ($8.5 million) and ($7.5 million) for Q2 2026.
• Focal One is not yet cleared or approved by the FDA for the treatment of BPH or endometriosis in the U.S., with use for these indications being investigational.

Risks

• There can be no assurance that the company's BPH development program will be successful or that Focal One will receive regulatory clearance or approval for this indication.
• There can be no assurance that Focal One will receive clearance or approval for the endometriosis indication in the United States.
• The preliminary results are based on several assumptions and are subject to a number of risks and uncertainties, and actual results may differ materially.
• Factors that could cause actual results to differ materially include clinical status and market acceptance of HIFU devices, continued market potential for ESWL and Distribution divisions, and global economic, political, and geopolitical instability.
• Risks associated with the current worldwide inflationary environment, uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics, or other public health crises.

Future Outlook

The company is focused on accelerating commercial execution, expanding its sales pipeline, and building long-term shareholder value. Key growth drivers include expanding the addressable market through new indications like BPH and endometriosis, and continued innovation in HIFU and histotripsy technology.

Management Comments

• The Company is advancing the evaluation of its Focal One Robotic HIFU platform for the potential treatment of benign prostatic hyperplasia ("BPH").
• The Company believes its robotic HIFU technology may provide a non-invasive treatment alternative for deep infiltrating endometriosis.
• Strong commercial execution with record second quarter HIFU Revenue.
• Accelerated adoption across leading hospital networks with four additional health systems purchasing a second or subsequent system during the quarter.
• Growing international expansion with new installations at Imperial College Healthcare NHS Trust London, Nice University Hospital, and leading centers in India.
• Investing Today to Build and Lead the Global Category of Robotic Focal Therapy.

Industry Context

StockSavvy.ai notes that FocalTherics is positioning itself within the growing field of therapeutic ultrasound and minimally invasive treatments. The company's strategic shift to focus on its high-growth HIFU segment and expansion into large markets like BPH and endometriosis aligns with broader industry trends towards organ-sparing and function-preserving medical interventions.

Comparison to Industry Standards

• The HIFI trial, a prospective, comparative, multicentric, non-inferiority clinical trial, demonstrated comparable cancer control at 30 months (90% STFS for HIFU vs 86% for RP) and superior functional outcomes for HIFU compared to Radical Prostatectomy (RP).
• The FARP randomized controlled trial showed equivalent oncologic control at 3 years (93.5% TFF vs 91.5%) after focal ablation compared to Robot-Assisted Radical Prostatectomy (RP), with superior functional outcomes after focal ablation.
• HIFU demonstrates equivalent 10-year survival to Radiation Therapy (EBRT), with lower overall mortality (9.2% vs 16.7%) and cancer-specific mortality (5.4% vs 9.2%) post-HIFU.
• The company highlights that HIFU provides the highest physician payment among focal ablation treatments for prostate cancer based on Medicare Physician Fee Schedule data.
• The company's Focal One Robotic HIFU is presented as a superior alternative to traditional treatments like surgery and radiation for prostate cancer, offering better quality of life preservation.
• The company's technology is positioned against competitors in ablation therapy for prostate cancer, with HIFU being highlighted as the fastest-growing treatment option.

Stakeholder Impact

• Shareholders: Potential for increased valuation due to strong revenue growth and expansion into new markets, but tempered by the preliminary nature of results and ongoing operating losses.
• Patients: Access to potentially less invasive and more effective treatment options for prostate cancer, BPH, and endometriosis.
• Hospitals/Healthcare Systems: Opportunity to adopt advanced technology with growing reimbursement and clinical evidence, potentially improving patient outcomes and hospital ROI.
• Employees: Continued growth and development opportunities as the company expands its operations and market reach.

Next Steps

• Report full second quarter of 2026 financial results after market close on Thursday, August 13th.
• Hold a conference call on August 13th to discuss results.
• Continue feasibility studies for BPH treatment in the U.S. and internationally.
• Advance clinical development for endometriosis, including a randomized controlled pivotal study.
• Inform regulatory strategy for endometriosis using long-term data from European studies.
• Continue development of proprietary Focal One-based histotripsy technology.

Key Dates

Recommendation

The preliminary results show strong growth and promising expansion into new indications, which is positive. However, the company is still operating at a loss, and the results are unaudited and subject to change. The expansion into BPH and endometriosis is investigational in the U.S., adding a layer of regulatory risk. Therefore, a 'hold' recommendation is appropriate pending the release of audited full-year results and further clarity on regulatory pathways for new indications.

Keywords

HIFU, Focal Therapy, Prostate Cancer, Robotic Surgery, Medical Devices, BPH, Endometriosis, Financial Results